Surveyed U.S. Oncologists Indicate They Would Prescribe Rindopepimut to 36 Percent of Their Newly Diagnosed Glioblastoma Multiforme (GBM) Patients

However, Decision Resources Forecasts That Rindopepimut Will Earn an 18 Percent Patient Share in the Newly Diagnosed GBM Market in the United States by 2020

June 4, 2012—Burlington, Mass.—Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. oncologists indicate that they would prescribe the emerging vaccine rindopepimut (Celldex Therapeutics’ CDX-110) to 36 percent of their newly diagnosed glioblastoma multiforme (GBM) patients. Decision Resources forecasts that rindopepimut will earn an 18 percent patient share in the U.S. newly diagnosed GBM market by 2020 because only about one-third of GBM patients harbor the appropriate EGFRVIII variant targeted by rindopepimut—this factor, combined with increased competition in the GBM market, will limit the patient population eligible for the therapy.

The DecisionBase 2012 report entitled Newly Diagnosed Glioblastoma: Avastin’s Future Hangs in the Balance as Oncologists Await Phase III Data: Which Other Emerging Drugs Excite Them? also finds that surveyed U.S. oncologists and managed care organization (MCO) pharmacy directors agree that overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in newly diagnosed GBM.

“In addition to extending overall survival, surveyed oncologists and MCO pharmacy directors highlight the need to improve a patient’s quality of life as one of the greatest unmet needs in treating this disease,” said Decision Resources Therapeutic Area Director Joanne Graham, Ph.D.

Clinical data and interviewed thought leaders indicate that bevacizumab (Roche/Genentech/Chugai’s Avastin) and two emerging vaccines, rindopepimut and ICT-107 (ImmunoCellular Therapeutics), when each is added to temozolomide (Merck & Co.’s Temodar/Temodal, generics) have demonstrated the potential to partially fulfill these unmet needs.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at


All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Search Reports

Decision Resources Group brands include: